2.07 0 (0%) | 11-15 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 2.41 | 1-year : | 2.82 |
Resists | First : | 2.06 | Second : | 2.41 |
Pivot price | 2.06 | |||
Supports | First : | 2.04 | Second : | 2.02 |
MAs | MA(5) : | 2.06 | MA(20) : | 2.06 |
MA(100) : | 0.95 | MA(250) : | 1.05 | |
MACD | MACD : | 0.1 | Signal : | 0.1 |
%K %D | K(14,3) : | 100 | D(3) : | 88.8 |
RSI | RSI(14): 83.9 | |||
52-week | High : | 3.4 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LOGC ] has closed below upper band by 28.9%. Bollinger Bands are 94.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.07 - 2.08 | 2.08 - 2.09 |
Low: | 2.04 - 2.05 | 2.05 - 2.06 |
Close: | 2.05 - 2.07 | 2.07 - 2.09 |
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
Wed, 16 Nov 2022
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics - Business Wire
Mon, 03 Oct 2022
LOGC stock jumps on buyout deal with AstraZeneca unit Alexion (NASDAQ:LOGC) - Seeking Alpha
Mon, 03 Oct 2022
Why Are LogicBio Therapeutics Shares Skyrocketing Today? - Yahoo Finance
Mon, 03 Oct 2022
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine - Business Wire
Mon, 09 May 2022
LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial - Yahoo Finance
Tue, 22 Dec 2020
Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer - BioSpace
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 33 (M) |
Shares Float | 17 (M) |
Held by Insiders | 8.9 (%) |
Held by Institutions | 50.1 (%) |
Shares Short | 134 (K) |
Shares Short P.Month | 29 (K) |
EPS | -1.12 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.62 |
Profit Margin | 0 % |
Operating Margin | -296.1 % |
Return on Assets (ttm) | -30.2 % |
Return on Equity (ttm) | -94.5 % |
Qtrly Rev. Growth | 298.8 % |
Gross Profit (p.s.) | -0.7 |
Sales Per Share | 0.3 |
EBITDA (p.s.) | -0.9 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -28 (M) |
Levered Free Cash Flow | -12 (M) |
PE Ratio | -1.86 |
PEG Ratio | 0 |
Price to Book value | 3.28 |
Price to Sales | 6.71 |
Price to Cash Flow | -2.41 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |